Vical has signed a license agreement with the Wistar Institute that grants Vical exclusive, worldwide rights to Wistar's Towne strain of cytomegalovirus and related technologies.
Subscribe to our email newsletter
The Towne strain is an attenuated, or weakened, form of human cytomegalovirus (CMV) developed for potential vaccine applications.
Vijay Samant, president and CEO of Vical, said: “CMV is an important target for Vical, and the Wistar technology adds to our already-strong intellectual property in this field.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.